A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity Characteristics and Preliminary Efficacy of Multiple Ascending Doses of HC022 Injection in Subjects With Systemic Lupus Erythematosus and/or Cutaneous Lupus Erythematosus
Latest Information Update: 04 Feb 2026
At a glance
- Drugs HC 022 (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors HC Biopharma
Most Recent Events
- 02 Jan 2026 New trial record